Comparative efficacy of fruquintinib, regorafenib or TAS-102 in patients with KRAS-mutant metastatic colorectal cancer: a systematic review and network meta-analysis
This study aimed to synthesize evidence from recent randomized controlled trials (RCTs) evaluating the efficacy of regorafenib, fruquintinib, and TAS-102 in patients with metastatic colorectal cancer (mCRC). Using a network meta-analysis, we compared long-term survival outcomes (overall and progression-free surviva...